PMID- 26742883
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20160119
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 57
IP  - 1
DP  - 2016
TI  - Long-Term Adaptive Servo-Ventilator Treatment Prevents Cardiac Death and Improves 
      Clinical Outcome.
PG  - 47-52
LID - 10.1536/ihj.15-229 [doi]
AB  - Adaptive servo-ventilation (ASV) is a recently developed, noninvasive therapeutic 
      tool for the treatment of heart failure (HF). However, the efficacy of ASV 
      therapy in patients with advanced HF remains uncertain, especially as regards its 
      contribution to freedom from cardiac replacement therapy. A total of 85 patients 
      with advanced HF (New York Heart Association [NYHA] class IV 71%, inotrope 
      infusion-dependent 34%) refractory to guideline-directed medical therapy, 
      received ASV therapy, irrespective of sleep-disordered breathing, at our 
      institute between 2008 and 2014. Among these 85 patients, 46 continued ASV 
      therapy for > 1 month (continued group), whereas 39 discontinued the therapy 
      after < 1 month because of intolerance (discontinued group). There were no 
      significant differences in baseline variables between the two groups. Heart rate 
      indicating sympathetic activity, left ventricular (LV) reverse remodeling 
      assessed by LV diastolic diameter, LV ejection fraction, and the grades of mitral 
      and tricuspid regurgitations, HF severity assessed by NYHA class and plasma level 
      of B-type natriuretic peptide, and end-organ dysfunction, improved significantly 
      at 6 months following the initiation of ASV therapy (P < 0.05 for all). All-cause 
      mortality and cardiac death rate were significantly lower during 2-year follow up 
      in the continued group (P < 0.05 for both). In conclusion, ASV is a novel 
      therapeutic tool prior to cardiac replacement therapy in patients with advanced 
      HF and may prolong the period until cardiac replacement therapy becomes 
      necessary.
FAU - Imamura, Teruhiko
AU  - Imamura T
AD  - Department of Therapeutic Strategy for Heart Failure, Graduate School of 
      Medicine, The University of Tokyo.
FAU - Kinugawa, Koichiro
AU  - Kinugawa K
FAU - Nitta, Daisuke
AU  - Nitta D
FAU - Komuro, Issei
AU  - Komuro I
LA  - eng
PT  - Journal Article
DEP - 20160108
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
SB  - IM
MH  - Cause of Death/trends
MH  - Death, Sudden, Cardiac/epidemiology/etiology/*prevention & control
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/complications/mortality/*therapy
MH  - Humans
MH  - Incidence
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Respiration, Artificial/*methods
MH  - Retrospective Studies
MH  - Survival Rate/trends
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2016/01/09 06:00
MHDA- 2016/05/20 06:00
CRDT- 2016/01/09 06:00
PHST- 2016/01/09 06:00 [entrez]
PHST- 2016/01/09 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
AID - 10.1536/ihj.15-229 [doi]
PST - ppublish
SO  - Int Heart J. 2016;57(1):47-52. doi: 10.1536/ihj.15-229. Epub 2016 Jan 8.